Atypical femoral fracture in a metastatic bone disease patient six months after discontinuation of denosumab received sequentially to previous bisphosphonate therapy - A case report

Although, both bisphosphonates and denosumab are effective in reducing the risk of skeletal-related events in patients with metastatic bone disease, many concerns were being raised about the possible association between their use and atypical femoral fractures. A case of an atypical femoral fracture...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiadis, George F., Balanika, Alexia P., Vasilakis, Alexandros Ε., Begkas, Dimitrios G., Baltas, Christos S., Pastroudis, Alexandros P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Society of Musculoskeletal and Neuronal Interactions 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426652/
https://www.ncbi.nlm.nih.gov/pubmed/34465683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426652/
https://www.ncbi.nlm.nih.gov/pubmed/34465683

Ejemplares similares